Investor Relations


Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections. Our lead product candidate, lefamulin, is being developed as the first pleuromutilin antibiotic for intravenous (IV) and oral administration in humans. We reported positive topline efficacy and favorable tolerability results from the LEAP 1 and LEAP 2 pivotal Phase 3 trials for the treatment of community-acquired bacterial pneumonia (CABP) in adults. We believe lefamulin has the potential to be developed for additional uses and we are working to build a robust pipeline of products. Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

More events are coming soon.

Wednesday January 23, 2019 8:30 AM EST
Nabriva Analyst & Investor Day

Tuesday November 27, 2018 11:00 AM EST
Piper Jaffray Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

Current Reports

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings
View HTML EX-101.INS - EX-101.INS

Securities offered to employees pursuant to employee benefit plans

Registration Statements

Investor Contacts

David Garrett
Vice President, Corporate Controller and Head of Investor Relations Nabriva Therapeutics plc